FIELD: chemistry; pharmaceutics.
SUBSTANCE: invention relates to organic chemistry and pharmaceutics, specifically a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof, compound 218, its enantiomers, pharmaceutically acceptable salts which bind Cereblon for breaking down the Ikaros protein or the Aiolos protein via the ubiquitin-proteasome pathway, a pharmaceutical composition based thereon, their use for the preparation of a therapeutic agent and a method of treating a disorder which is cancer or a tumour mediated by cerebellum in a human being. In general formula I or formula II, X1 and X2 are independently selected from CH and N; X3 is selected from communication, NR2, C(R3R3’), O, C(O), C(S), S, S(O) and S(O)2; R1 is selected from hydrogen, halogen, cyano, nitro, NH2, -OH, -NR2R4, -OR4, -(CR3R3’)-R4, -C(O)R4, -SR4, -S(O)R4 and -S(O)2R4; R20, R21, R22, R23 and R24 independently in each case are selected from a group consisting of a bond, C1-C4 alkyl, -C(O)-, -C(O)O-, -OC(O)-, -SO2-, -S(O)-, -C(S)-, -C(O)NR2-, -NR2C(O)-, -O-, -S-, -NR2-, -P(O)(R28)-, -P(O)-, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C6-C14 aryl, 3–14-membered heterocycle with 1–3 heteroatoms selected from nitrogen, sulphur and oxygen, 5–10-member heteroaryl with 1–3 heteroatoms selected from nitrogen, sulphur and oxygen, bicyclic and C3-C8 cycloalkyl; each of them is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R40; and where R20, R21, R22, R23 and R24 cannot be selected so that -C(O)-, -C(O)O-, -OC(O)-, -SO2-, -S(O)-, -P(O)(R28)-, -P(O)- and -C(S)- fragments are adjacent to each other; or -O-, -S- or -NR2- fragments are adjacent to each other; R25 is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen, hydroxyl, C1-C4 alkoxy, azide, amino, cyano, -OR2, -NR2R2’, -NR2SO2R28, -OSO2R28, -SO2R28, C1-C4 haloalkyl, C6-C14 aryl, 5–10-membered heteroaryl with 1–3 heteroatoms selected from nitrogen, sulphur and oxygen, 3–14-membered heterocycle with 1–3 heteroatoms selected from nitrogen, sulphur and oxygen, bicycle and C3-C8 cycloalkyl; each of such R25 groups is optionally substituted with 1, 2, 3 or 4 groups independently selected from R12. Other values of radicals are given in the claim.
EFFECT: disclosed are tricyclic compounds which provide for the destruction of the Ikaros protein and the Aiolos protein.
233 cl, 2 tbl, 295 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS TARGETING TAU PROTEIN AND RELATED USE THEREOF | 2017 |
|
RU2805523C2 |
POLYCYCLIC COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF POLYPEPTIDES OF FAST ACCELERATED FIBROSARCOMA | 2019 |
|
RU2830173C2 |
THIENOPYRAZOLES | 2004 |
|
RU2358978C2 |
HYDROXYPURINE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2685417C1 |
5-AZAINDAZOLE COMPOUNDS AND METHODS FOR USE THEREOF | 2013 |
|
RU2665462C2 |
KINASE INHIBITORS | 2013 |
|
RU2637944C2 |
AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND USE THEREOF AS INHIBITORS OF UBIQUITIN-SPECIFIC PROCESSING PROTEASE 1 (USP1) | 2019 |
|
RU2833222C2 |
CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND VARIANTS OF THEIR USE | 2018 |
|
RU2795850C2 |
Authors
Dates
2025-01-27—Published
2020-04-10—Filed